[go: up one dir, main page]

MX2009003300A - Vectores de rhinovirus recombinantes. - Google Patents

Vectores de rhinovirus recombinantes.

Info

Publication number
MX2009003300A
MX2009003300A MX2009003300A MX2009003300A MX2009003300A MX 2009003300 A MX2009003300 A MX 2009003300A MX 2009003300 A MX2009003300 A MX 2009003300A MX 2009003300 A MX2009003300 A MX 2009003300A MX 2009003300 A MX2009003300 A MX 2009003300A
Authority
MX
Mexico
Prior art keywords
rhinovirus vectors
recombinant rhinovirus
recombinant
vectors
methods
Prior art date
Application number
MX2009003300A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Harold Kleanthous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of MX2009003300A publication Critical patent/MX2009003300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32741—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona vectores de rhinovirus recombinantes, por ejemplo, antígenos del virus de la influenza. También provistos en la invención son composiciones farmacéuticas y métodos correspondientes.
MX2009003300A 2006-09-29 2007-10-01 Vectores de rhinovirus recombinantes. MX2009003300A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84830806P 2006-09-29 2006-09-29
US88066407P 2007-01-15 2007-01-15
PCT/US2007/021102 WO2008100290A2 (en) 2006-09-29 2007-10-01 Recombinant rhinovirus vectors

Publications (1)

Publication Number Publication Date
MX2009003300A true MX2009003300A (es) 2009-08-12

Family

ID=39690648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003300A MX2009003300A (es) 2006-09-29 2007-10-01 Vectores de rhinovirus recombinantes.

Country Status (11)

Country Link
US (1) US20100239605A1 (es)
EP (1) EP2069483A4 (es)
JP (1) JP2010504760A (es)
KR (1) KR20090096414A (es)
CN (1) CN101688184A (es)
AU (1) AU2007347184A1 (es)
BR (1) BRPI0717157A2 (es)
CA (1) CA2664791A1 (es)
IL (1) IL197756A0 (es)
MX (1) MX2009003300A (es)
WO (1) WO2008100290A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120380A2 (en) * 2008-03-27 2009-10-01 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP2970396B1 (en) * 2013-03-15 2022-02-23 Biological Mimetics, Inc. Immunogenic human rhinovirus (hrv) compositions
US20230330208A1 (en) * 2013-03-15 2023-10-19 Biological Mimetics, Inc. Immunogenic Human Rhinovirus (HRV) Composition
JP2015120709A (ja) * 2015-01-09 2015-07-02 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィーＬａｂｏｒａｔｏｒｉｏ Ａｖｉ−Ｍｅｘ，Ｓ．Ａ． Ｄｅ Ｃ．Ｖ． 遺伝子組み換え不活性化ウィルスベクターワクチン

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752473A (en) 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
AU2775692A (en) 1991-08-30 1994-04-12 Smithkline Beecham Corporation Recombinant influenza virus vaccine compositions
WO1993015763A1 (en) 1992-02-18 1993-08-19 Smithkline Beecham Corporation Vaccinal polypeptides
US6582902B1 (en) * 1992-09-30 2003-06-24 Jack D. Keene Method for deriving epitopes
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5374717A (en) 1992-09-30 1994-12-20 The United States Of America As Represented By The Secretary Of Health And Human Services Sequences of the hemagglutinins of recent strains of influenza type B virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5338311A (en) * 1993-08-23 1994-08-16 Mahurkar Sakharam D Hypodermic needle assembly
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
DK0996717T3 (da) 1997-08-05 2006-04-10 Vlaams Interuniv Inst Biotech Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
AU4078599A (en) 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
GB9815040D0 (en) 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
HK1052949B (en) 2000-04-14 2011-04-29 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
CA2410297C (en) 2000-06-23 2011-03-15 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7449188B2 (en) * 2001-01-18 2008-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Recombinant oligometric protein complexes with enhanced immunogenic potential
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
US7569383B2 (en) * 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
US20040146524A1 (en) 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185854A1 (en) 2002-02-08 2003-10-02 Fidel Zavala Use of recombinant hepatitis B core particles to develop vaccines against infectious pathogens and malignancies
EP1517702A4 (en) 2002-02-21 2006-05-03 Apovia Inc IMMUNOGENIC HBC CHIMERIC PARTICLES STABILIZED WITH AN N-TERMINAL END CYSTEINE
AU2003300841B2 (en) 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
WO2004064784A2 (en) * 2003-01-16 2004-08-05 The Wistar Institute Composition and method for preventing or treating a virus infection
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
CN1809633B (zh) 2003-04-23 2011-01-19 威斯康星旧生研究基金会 跨膜蛋白基因中含有突变的重组流感病毒
US8475806B2 (en) 2003-05-28 2013-07-02 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060088549A1 (en) 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
EP1853307B1 (en) 2005-02-01 2016-12-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
AU2007318206A1 (en) * 2006-09-29 2008-05-15 Sanofi Pasteur Biologics Co. Novel neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications
WO2008094674A1 (en) * 2007-01-31 2008-08-07 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
WO2009099678A1 (en) * 2008-02-09 2009-08-13 Sanofi Pasteur Biologics Co. Influenza b vaccines
CA2717499A1 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
WO2009120380A2 (en) * 2008-03-27 2009-10-01 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors

Also Published As

Publication number Publication date
WO2008100290A3 (en) 2008-11-06
CA2664791A1 (en) 2008-08-21
AU2007347184A2 (en) 2009-11-12
JP2010504760A (ja) 2010-02-18
WO2008100290A2 (en) 2008-08-21
KR20090096414A (ko) 2009-09-10
AU2007347184A1 (en) 2008-08-21
BRPI0717157A2 (pt) 2013-10-15
WO2008100290A9 (en) 2008-12-24
IL197756A0 (en) 2011-08-01
EP2069483A4 (en) 2010-10-27
CN101688184A (zh) 2010-03-31
US20100239605A1 (en) 2010-09-23
EP2069483A2 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
EA201100268A1 (ru) Вакцина
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2010004374A (es) Armazones proteinicos.
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
NO20092611L (no) Krystallinsk faststoff Rasagilin base
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2008051942A3 (en) Farnesoid x receptor agonists
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
IN2012DN02368A (es)
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2008070269A3 (en) Methods, software and systems for imaging
WO2006104945A3 (en) Hepatitis c therapies
WO2009130479A3 (en) Virus
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX2010005589A (es) Composicion para el cuidado personal.
IL176142A0 (en) Processes for preparing montelukast sodium
IL189452A0 (en) Therapy with cd4 binding peptides and radiation

Legal Events

Date Code Title Description
HH Correction or change in general